Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy.

Chakraborty A, Kamermans A, van Het Hof B, Castricum K, Aanhane E, van Horssen J, Thijssen VL, Scheltens P, Teunissen CE, Fontijn RD, van der Flier WM, de Vries HE.

Brain. 2018 Dec 1;141(12):3377-3388. doi: 10.1093/brain/awy274.

PMID:
30462206
2.

α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.

van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA.

Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15.

PMID:
30440090
3.

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC, van Marum RJ, Roks G, Schoonenboom N, Verwey N, Zwan MD, Wahl S, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Sep 12;10:563-572. doi: 10.1016/j.dadm.2018.08.006. eCollection 2018.

4.

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study.

Hum Brain Mapp. 2018 Oct 19. doi: 10.1002/hbm.24401. [Epub ahead of print]

PMID:
30368979
5.

Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.

Ten Kate M, Dicks E, Visser PJ, van der Flier WM, Teunissen CE, Barkhof F, Scheltens P, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2018 Dec 1;141(12):3443-3456. doi: 10.1093/brain/awy264.

PMID:
30351346
6.

Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease.

Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, Ourselin S, Scheltens P, Cardoso MJ, van der Flier WM, Ossenkoppele R.

Neurology. 2018 Nov 13;91(20):e1851-e1859. doi: 10.1212/WNL.0000000000006503. Epub 2018 Oct 19.

PMID:
30341156
7.

Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies.

Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F.

Alzheimers Dement. 2018 Oct 12. pii: S1552-5260(18)33527-1. doi: 10.1016/j.jalz.2018.09.002. [Epub ahead of print]

PMID:
30321506
8.

Evaluating combinations of diagnostic tests to discriminate different dementia types.

Bruun M, Rhodius-Meester HFM, Koikkalainen J, Baroni M, Gjerum L, Lemstra AW, Barkhof F, Remes AM, Urhemaa T, Tolonen A, Rueckert D, van Gils M, Frederiksen KS, Waldemar G, Scheltens P, Mecocci P, Soininen H, Lötjönen J, Hasselbalch SG, van der Flier WM.

Alzheimers Dement (Amst). 2018 Aug 17;10:509-518. doi: 10.1016/j.dadm.2018.07.003. eCollection 2018.

9.

Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease.

Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA.

Neurobiol Aging. 2019 Jan;73:230.e9-230.e17. doi: 10.1016/j.neurobiolaging.2018.09.007. Epub 2018 Sep 15.

PMID:
30314815
10.

Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study.

Leeuwis AE, Smith LA, Melbourne A, Hughes AD, Richards M, Prins ND, Sokolska M, Atkinson D, Tillin T, Jäger HR, Chaturvedi N, van der Flier WM, Barkhof F.

Front Aging Neurosci. 2018 Sep 18;10:279. doi: 10.3389/fnagi.2018.00279. eCollection 2018.

11.

Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease.

Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H.

Eur J Hum Genet. 2018 Sep 26. doi: 10.1038/s41431-018-0273-5. [Epub ahead of print]

PMID:
30258121
12.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalski EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumurgier J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Laforce RJ, Visser PJ, Ossenkoppele R.

Ann Neurol. 2018 Nov;84(5):729-740. doi: 10.1002/ana.25333.

PMID:
30255971
13.

Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals.

Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ; for ADNI.

Ann Clin Transl Neurol. 2018 Jul 20;5(9):1037-1047. doi: 10.1002/acn3.615. eCollection 2018 Sep.

14.

Is intracranial volume a suitable proxy for brain reserve?

van Loenhoud AC, Groot C, Vogel JW, van der Flier WM, Ossenkoppele R.

Alzheimers Res Ther. 2018 Sep 11;10(1):91. doi: 10.1186/s13195-018-0408-5. Review.

15.

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.

Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM.

Ann Neurol. 2018 Nov;84(5):648-658. doi: 10.1002/ana.25334. Epub 2018 Oct 4.

PMID:
30196548
16.

The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study.

Haaksma ML, Rizzuto D, Ramakers IHGB, Garcia-Ptacek S, Marengoni A, van der Flier WM, Verhey FRJ, Olde Rikkert MGM, Melis RJF.

J Am Med Dir Assoc. 2018 Aug 23. pii: S1525-8610(18)30358-X. doi: 10.1016/j.jamda.2018.06.020. [Epub ahead of print]

PMID:
30145169
17.

Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.

Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM; Amsterdam Dementia Cohort, Alzheimer’s Disease Neuroimaging Initiative, German Dementia Competence Network, University of San Francisco Memory and Aging Center.

J Alzheimers Dis. 2018;65(3):1029-1039. doi: 10.3233/JAD-171088.

PMID:
30103316
18.

Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change.

Reus LM, Vijverberg EG, Tijms BM, Kate MT, Gossink F, Krudop WA, Campo MD, Teunissen CE, Barkhof F, van der Flier WM, Visser PJ, Dols A, Pijnenburg YA.

J Psychiatr Res. 2018 Sep;104:183-191. doi: 10.1016/j.jpsychires.2018.07.014. Epub 2018 Aug 1.

PMID:
30103065
19.

Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review.

Doorduijn AS, van de Rest O, van der Flier WM, Visser M, de van der Schueren MAE.

J Am Med Dir Assoc. 2018 Aug 9. pii: S1525-8610(18)30357-8. doi: 10.1016/j.jamda.2018.06.019. [Epub ahead of print] Review.

PMID:
30100233
20.

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.

Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM.

Alzheimers Res Ther. 2018 Aug 7;10(1):76. doi: 10.1186/s13195-018-0390-y.

21.

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, Scheltens P, van der Flier WM.

Alzheimers Res Ther. 2018 Jul 28;10(1):72. doi: 10.1186/s13195-018-0398-3. Review.

22.

Survival in memory clinic cohort is short, even in young-onset dementia.

Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman F, Scheltens P, van der Flier WM.

J Neurol Neurosurg Psychiatry. 2018 Jul 25. pii: jnnp-2018-318820. doi: 10.1136/jnnp-2018-318820. [Epub ahead of print] No abstract available.

23.

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease.

Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, Lammertsma AA, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Pijnenburg YAL, Yaqub M, Ossenkoppele R, van Berckel BNM.

Neuroimage Clin. 2018 May 22;19:625-632. doi: 10.1016/j.nicl.2018.05.024. eCollection 2018.

24.

Wishes and preferences for an online lifestyle program for brain health-A mixed methods study.

Wesselman LMP, Schild AK, Coll-Padros N, van der Borg WE, Meurs JHP, Hooghiemstra AM, Slot RER, Sannemann L, Rami L, Molinuevo JL, Bouwman FH, Jessen F, van der Flier WM, Sikkes SAM; Euro-SCD working group.

Alzheimers Dement (N Y). 2018 Apr 9;4:141-149. doi: 10.1016/j.trci.2018.03.003. eCollection 2018.

25.

Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.

Chakraborty A, Chatterjee M, Twaalfhoven H, Del Campo Milan M, Teunissen CE, Scheltens P, Fontijn RD, van Der Flier WM, de Vries HE.

Alzheimers Res Ther. 2018 Jun 23;10(1):58. doi: 10.1186/s13195-018-0385-8.

26.

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Rikkert MO, van der Flier WM, Scheltens P, Aalten P, Visser PJ, Vos SJB.

Alzheimers Res Ther. 2018 Jun 20;10(1):56. doi: 10.1186/s13195-018-0391-x.

27.

Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier.

Tolonen A, Rhodius-Meester HFM, Bruun M, Koikkalainen J, Barkhof F, Lemstra AW, Koene T, Scheltens P, Teunissen CE, Tong T, Guerrero R, Schuh A, Ledig C, Baroni M, Rueckert D, Soininen H, Remes AM, Waldemar G, Hasselbalch SG, Mecocci P, van der Flier WM, Lötjönen J.

Front Aging Neurosci. 2018 Apr 25;10:111. doi: 10.3389/fnagi.2018.00111. eCollection 2018.

28.

Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease.

Barnes J, Bartlett JW, Wolk DA, van der Flier WM, Frost C.

J Alzheimers Dis. 2018;64(2):631-642. doi: 10.3233/JAD-170841.

29.

Quantification of [18F]florbetapir: A test-retest tracer kinetic modelling study.

Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, Timmers T, Groot C, Schober P, Scheltens P, van der Flier WM, Windhorst AD, van Berckel BN, Lammertsma AA.

J Cereb Blood Flow Metab. 2018 Jun 13:271678X18783628. doi: 10.1177/0271678X18783628. [Epub ahead of print]

PMID:
29897009
30.

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.

de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, van Buchem MM, Zwan M, Ossenkoppele R, Yaqub M, Kunneman M, Smets EMA, Barkhof F, Lammertsma AA, Stephens A, van Lier E, Biessels GJ, van Berckel BN, Scheltens P.

JAMA Neurol. 2018 Sep 1;75(9):1062-1070. doi: 10.1001/jamaneurol.2018.1346.

PMID:
29889941
31.

Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.

Chatterjee M, Del Campo M, Morrema THJ, de Waal M, van der Flier WM, Hoozemans JJM, Teunissen CE.

Alzheimers Res Ther. 2018 Jun 1;10(1):52. doi: 10.1186/s13195-018-0383-x.

32.

Microbleeds are associated with depressive symptoms in Alzheimer's disease.

Leeuwis AE, Prins ND, Hooghiemstra AM, Benedictus MR, Scheltens P, Barkhof F, van der Flier WM.

Alzheimers Dement (Amst). 2017 Dec 6;10:112-120. doi: 10.1016/j.dadm.2017.11.006. eCollection 2018.

33.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
34.

Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction.

Amier RP, Smulders MW, van der Flier WM, Bekkers SCAM, Zweerink A, Allaart CP, Demirkiran A, Roos ST, Teunissen PFA, Appelman Y, van Royen N, Kim RJ, van Rossum AC, Nijveldt R.

JACC Cardiovasc Imaging. 2018 Dec;11(12):1773-1781. doi: 10.1016/j.jcmg.2018.02.009. Epub 2018 Apr 18.

35.

Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam.

van den Kommer TN, Deeg DJH, van der Flier WM, Comijs HC.

J Gerontol B Psychol Sci Soc Sci. 2018 Apr 16;73(suppl_1):S57-S64. doi: 10.1093/geronb/gbx151.

PMID:
29669101
36.

Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging.

Bouts MJRJ, Möller C, Hafkemeijer A, van Swieten JC, Dopper E, van der Flier WM, Vrenken H, Wink AM, Pijnenburg YAL, Scheltens P, Barkhof F, Schouten TM, de Vos F, Feis RA, van der Grond J, de Rooij M, Rombouts SARB.

J Alzheimers Dis. 2018;62(4):1827-1839. doi: 10.3233/JAD-170893.

PMID:
29614652
37.

European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.

Vermunt L, Veal CD, Ter Meulen L, Chrysostomou C, van der Flier W, Frisoni GB, Guessous I, Kivipelto M, Marizzoni M, Martinez-Lage P, Molinuevo JL, Porteous D, Ritchie K, Scheltens P, Ousset PJ, Ritchie CW, Luscan G, Brookes AJ, Visser PJ.

Alzheimers Dement. 2018 Jun;14(6):837-842. doi: 10.1016/j.jalz.2018.02.010. Epub 2018 Mar 28.

PMID:
29604264
38.

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline.

Verfaillie SCJ, Slot RER, Dicks E, Prins ND, Overbeek JM, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM, Tijms BM.

Hum Brain Mapp. 2018 Aug;39(8):3143-3151. doi: 10.1002/hbm.24065. Epub 2018 Mar 30.

39.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
40.

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults.

Ten Kate M, Visser PJ, Bakardjian H, Barkhof F, Sikkes SAM, van der Flier WM, Scheltens P, Hampel H, Habert MO, Dubois B, Tijms BM.

Front Aging Neurosci. 2018 Mar 15;10:67. doi: 10.3389/fnagi.2018.00067. eCollection 2018.

41.

Amsterdam Dementia Cohort: Performing Research to Optimize Care.

van der Flier WM, Scheltens P.

J Alzheimers Dis. 2018;62(3):1091-1111. doi: 10.3233/JAD-170850.

42.

Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.

Leijenaar JF, Groeneveld GJ, van der Flier WM, Scheltens P, Klaassen ES, Weinstein HC, Biessels GJ, Barkhof F, Prins ND.

JMIR Res Protoc. 2018 Mar 20;7(3):e80. doi: 10.2196/resprot.9192.

43.

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study.

Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, Vanmechelen E, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE.

Clin Chem. 2018 Jun;64(6):927-937. doi: 10.1373/clinchem.2017.283028. Epub 2018 Mar 9.

PMID:
29523639
44.

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.

Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ, van der Flier WM, Teunissen CE, van Swieten JC, Pijnenburg YAL.

Neurology. 2018 Apr 3;90(14):e1231-e1239. doi: 10.1212/WNL.0000000000005261. Epub 2018 Mar 7.

45.

Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease.

Rhodius-Meester HFM, Liedes H, Koene T, Lemstra AW, Teunissen CE, Barkhof F, Scheltens P, van Gils M, Lötjönen J, van der Flier WM.

Alzheimers Res Ther. 2018 Feb 20;10(1):23. doi: 10.1186/s13195-018-0348-0.

46.

Vascular cognitive impairment.

van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P.

Nat Rev Dis Primers. 2018 Feb 15;4:18003. doi: 10.1038/nrdp.2018.3. Review.

PMID:
29446769
47.

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.

Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, Zetterberg H, Blennow K.

Alzheimers Res Ther. 2018 Jan 15;10(1):5. doi: 10.1186/s13195-017-0335-x.

48.

Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies.

van der Lee SJ, Teunissen CE, Pool R, Shipley MJ, Teumer A, Chouraki V, Melo van Lent D, Tynkkynen J, Fischer K, Hernesniemi J, Haller T, Singh-Manoux A, Verhoeven A, Willemsen G, de Leeuw FA, Wagner H, van Dongen J, Hertel J, Budde K, Willems van Dijk K, Weinhold L, Ikram MA, Pietzner M, Perola M, Wagner M, Friedrich N, Slagboom PE, Scheltens P, Yang Q, Gertzen RE, Egert S, Li S, Hankemeier T, van Beijsterveldt CEM, Vasan RS, Maier W, Peeters CFW, Jörgen Grabe H, Ramirez A, Seshadri S, Metspalu A, Kivimäki M, Salomaa V, Demirkan A, Boomsma DI, van der Flier WM, Amin N, van Duijn CM.

Alzheimers Dement. 2018 Jun;14(6):707-722. doi: 10.1016/j.jalz.2017.11.012. Epub 2018 Jan 6.

49.

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Olde Rikkert M, van der Flier WM, Scheltens P, Aalten P, Visser PJ, Vos SJB.

Alzheimers Res Ther. 2017 Dec 29;9(1):101. doi: 10.1186/s13195-017-0328-9. Erratum in: Alzheimers Res Ther. 2018 Jun 20;10(1):56.

50.

Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease.

Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R.

Neurology. 2018 Jan 9;90(2):e149-e156. doi: 10.1212/WNL.0000000000004802. Epub 2017 Dec 13.

PMID:
29237798

Supplemental Content

Loading ...
Support Center